

WEST**End of Result Set**

Generate Collection

Print

L2: Entry 10 of 10

File: DWPI

Jun 29, 1994

DERWENT-ACC-NO: 1995-241081

DERWENT-WEEK: 199532

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Nasal medicine.

INVENTOR: KAN, D; KAN, Y

PATENT-ASSIGNEE:

ASSIGNEE

CODE

KAN Y

KANYI

PRIORITY-DATA: 1993CN-0117300 (September 1, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1088454 A	June 29, 1994		000	A61K035/78

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
CN 1088454A	September 1, 1993	1993CN-0117300	

INT-CL (IPC): A61K 35/78

ABSTRACTED-PUB-NO: CN 1088454A

BASIC-ABSTRACT:

The medicine comprises 'Biyuanning' capsule for treating acute and chronic nasal sinusitis. It consists of such Chinese traditional medicine herbs and flower bud of lily magnolia, rhizoma corydalis, centipenda, peppermint, root of Chinese wild ginger, capsule of weeping forsythia, mother chrysanthemum and rhizome of chuanxiong and is made up through the processes of crushing, extracting and refining.

ADVANTAGE - The nasal medicine features high curative effect, non- toxicity, no side effects and no recurrence.

TITLE-TERMS: NASAL MEDICINE

DERWENT-CLASS: B04

CPI-CODES: B04-A10; B14-N04;

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1995-110535

WEST☐ **Generate Collection** **Print**

L2: Entry 9 of 10

File: DWPI

May 24, 2000

DERWENT-ACC-NO: 2000-483375

DERWENT-WEEK: 200043

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Oral and nasal mucosa electroosmotic therapeutic equipment

INVENTOR: LIU, M

PATENT-ASSIGNEE:

ASSIGNEE

CODE

LIU M

LIUMI

PRIORITY-DATA: 1999CN-0125611 (November 24, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1253839 A	May 24, 2000		001	A61M037/00

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
CN 1253839A	November 24, 1999	1999CN-0125611	

INT-CL (IPC): A61 M 37/00

ABSTRACTED-PUB-NO: CN 1253839A

BASIC-ABSTRACT:

NOVELTY - The medical electroosmotic therapeutic equipment by means of oronasal mucous membrane to make therapy is characterized by applying directional voltage to make effective component of liquid medicine penetrate into human body under the action of electric field, and reach to the required position to produce therapeutic effect. As compared with general electroosmotic therapeutic equipment said invention possesses the following advantages: 1. its voltage is low, technical structure is simple, reliability is high and safety is good; 2. as compared with skin, negative ion with large mass is easy to be introduced through mucous membrane; and 3. for head diseases, such as rhinitis, nasal sinusitis and laryngopharyngitis the ion-introduction through mucous membrane of head is very effective therapeutic method.

CHOSEN-DRAWING: Dwg.0

TITLE-TERMS: ORAL NASAL MUCOUS THERAPEUTIC EQUIPMENT

DERWENT-CLASS: B07 P34

CPI-CODES: B11-C04; B14-N04; B14-N05;

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-145662

Non-CPI Secondary Accession Numbers: N2000-359205

WEST**End of Result Set**☐ **Generate Collection** **Print**

L3: Entry 14 of 14

File: DWPI

Feb 4, 1983

DERWENT-ACC-NO: 1983-25667K

DERWENT-WEEK: 198311

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Magnesium senegenate anti:allergic and anti:leukaemic agent - is prepd. by treating senegenine with magnesium carbonate

INVENTOR: RAGOT, J M

PATENT-ASSIGNEE:

ASSIGNEE

CODE

TUBERY P R

TUBEI

PRIORITY-DATA: 1981FR-0014902 (July 28, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2510557 A	February 4, 1983		008	

INT-CL (IPC): A61K 31/19; C07C 62/32

ABSTRACTED-PUB-NO: FR 2510557A

BASIC-ABSTRACT:

Magnesium senegenate (I), is obtd. by hot extraction of roots of Securidaca longepedunculata to give an extract rich in senegenine (II). This extract is then treated with magnesium carbonate in an aqueous medium to give (I).

Anti-allergic agent for treatment of eozemas, psoriasis, asthma, and rhino-sinusitis, maintenance of remissions from plate scleroses and treatment of chronic lymphoid leukaemia. (II) is a known agent for eczema and psoriasis, but it can only be given orally and has an immunodepressant effect. (I) is more soluble and may be given by injection as well as orally. Its immunodepressant effect is minimal. The adult daily odsage is 100-600mg orally or 50-30 mg by injection.

TITLE-TERMS: MAGNESIUM ANTI ALLERGIC ANTI LEUKAEMIA AGENT PREPARATION TREAT
MAGNESIUM CARBONATE

DERWENT-CLASS: B01 B05

CPI-CODES: B05-A01B; B09-B; B12-A07; B12-C10; B12-D02; B12-E02; B12-G05; B12-K02; B12-L04;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

A212 A960 C710 G031 G032 G036 G038 G039 G060 G820

H4 H402 H462 H6 H602 H681 H8 J0 J012 J1

J152 M210 M211 M240 M283 M311 M321 M342 M353 M391

M411 M510 M520 M530 M541 M630 M720 M903 N161 N262
N513 P431 P446 P517 P632 P822 P924 P943 R023

Chemical Indexing M6 *02*

Fragmentation Code

M903 P431 P446 P517 P822 P924 P943 R023 R111 R231

UNLINKED-DERWENT-REGISTRY-NUMBERS: 1359S

UNLINKED-RING-INDEX-NUMBERS: 06384

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1983-025113

WEST☐

L3: Entry 13 of 14

File: DWPI

Dec 30, 1989

DERWENT-ACC-NO: 1990-215982

DERWENT-WEEK: 199028

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Diagnosing poly rhino-sinusitis - uses additional determin. of specific antigen in mucous nasal membrane with specific antiserum, as differential indicator

INVENTOR: GRAFSKAYA, L M; PORTENKO, G M

PATENT-ASSIGNEE:

ASSIGNEE

CODE

KALIN MED INST

KLMER

PRIORITY-DATA: 1987SU-4342257 (September 11, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
SU 1532874 A	December 30, 1989		000	

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
SU 1532874A	September 11, 1987	1987SU-4342257	

INT-CL (IPC): G01N 33/53

ABSTRACTED-PUB-NO: SU 1532874A

BASIC-ABSTRACT:

Polypous rhinosinusitis is distinguished from the oedemous-hyperplastic form as follows. The clinical and histological tests of the mucous nasal membrane are supplemented by determining the specific antigen in the mucous membrane using a specific antiserum. When its amt. exceeds the norm, then polypous rhinosinusitis is diagnosed, otherwise the oedemous-hyperplastic form is indicated.

ADVANTAGE - Accuracy of diagnosis is increased from 60 to 100%. Bul.48/30.12.89

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: DIAGNOSE POLY RHINO SINUS ADD DETERMINE SPECIFIC ANTIGEN MUCOUS NASAL MEMBRANE SPECIFIC ANTISERUM DIFFERENTIAL INDICATE

DERWENT-CLASS: B04 S03

CPI-CODES: B04-B04C2; B04-B04D4; B04-B04L; B11-C07A; B12-K04A;

EPI-CODES: S03-E14H4;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code
M423 M750 M903 N102 V791
Registry Numbers
1327U 0502U

Chemical Indexing M1 *02*
Fragmentation Code
M423 M760 M903 N102 V600 V644
Registry Numbers
1327U 0502U

Chemical Indexing M1 *03*
Fragmentation Code
M423 M781 M903 N102 P831 V600 V611
Registry Numbers
1327U 0502U

Chemical Indexing M6 *04*
Fragmentation Code
M903 P831 R515 R614 R621 R631
Registry Numbers
1327U 0502U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1990-093412

Non-CPI Secondary Accession Numbers: N1990-167741

WEST☐ **Generate Collection** **Print**

L3: Entry 12 of 14

File: DWPI

Apr 30, 1990

DERWENT-ACC-NO: 1990-374431

DERWENT-WEEK: 199050

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Treatment of infectious allergic rhino-sinusitis - uses specified drug as bacterial immuno-stimulator to reduce duration of treatment

INVENTOR: KOSENKO, V A; LANTSOV, A A ; MOROZOVA, Z F

PATENT-ASSIGNEE:

ASSIGNEE

CODE

THROAT NOSE SPEECH

THROR

PRIORITY-DATA: 1987SU-4245008 (May 26, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
SU 1560221 A	April 30, 1990		000	

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
SU 1560221A	May 26, 1987	1987SU-4245008	

INT-CL (IPC): A61K 39/08

ABSTRACTED-PUB-NO: SU 1560221A

BASIC-ABSTRACT:

Infectious allergic rhinosinusitis is treated more efficiently when 'Prodigiosin' (I) is used as bacterial immunostimulator in conjunction with the standard hyposensitising therapy, the latter consisting of intravenous injection of Ca gluconate, ascorbic acid and antihistamins. The treatment with (I) starts on the fifth or sixth day of the therapy, and is given in 50, 75 and 100 microgm. doses twice a week, over 25-30 days.

ADVANTAGE - Shorter treatment, increased success rate. Bul.16/30.4.90

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: TREAT INFECT ALLERGIC RHINO SINUS SPECIFIED DRUG BACTERIA IMMUNO
STIMULATING REDUCE DURATION TREAT

DERWENT-CLASS: B04

CPI-CODES: B02-P01; B03-F; B10-A07; B12-A06; B12-D02; B12-D06; B12-D07;

CHEMICAL-CODES:

Chemical Indexing M2 *01*
Fragmentation Code

F012 F013 F015 F019 F421 F499 H5 H521 H7 H720
H8 M1 M116 M126 M132 M210 M211 M215 M231 M240
M272 M281 M282 M320 M413 M431 M510 M523 M530 M540
M782 M903 M904 P220 P420 P431 P432 P924 V0 V160
Specific Compounds
12995M
Registry Numbers
1327U 0502U

Chemical Indexing M2 *02*

Fragmentation Code
A220 A960 C710 H4 H405 H484 H8 J0 J011 J1
J171 K0 L8 L814 L821 L831 M280 M315 M321 M332
M344 M349 M381 M391 M411 M431 M510 M520 M530 M540
M620 M630 M782 M903 M904 P420 P431 P432 P924
Specific Compounds
04225M
Registry Numbers
1327U 0502U

Chemical Indexing M2 *03*

Fragmentation Code
F012 F013 F014 F015 F113 H4 H403 H421 H482 H8
J5 J522 K0 L8 L818 L821 L832 L9 L942 L960
M280 M312 M321 M332 M343 M373 M391 M413 M431 M510
M521 M530 M540 M782 M903 M904 M910 P420 P431 P432
P924 V0 V330
Specific Compounds
00035M
Registry Numbers
1327U 0502U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0035U; 1327U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1990-163141

WEST☐ **Generate Collection** **Print**

L3: Entry 10 of 14

File: DWPI

Feb 6, 1997

DERWENT-ACC-NO: 1997-145197

DERWENT-WEEK: 199928

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Use of non-steroidal anti-inflammatory drugs - e.g. paracetamol, diclofenac or ibuprofen for treatment of upper respiratory tract disorders and of intestinal, e.g. colon, polyps

INVENTOR: JUERGENS, U; JUERGENS, U R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

JUERGENS U

JUERI

JUERGENS U R

JUERI

PRIORITY-DATA: 1995DE-1026425 (July 20, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9703659 A1	February 6, 1997	G	015	A61K031/00
DE 29680627 U1	June 2, 1999		000	A61K031/19
AU 9665122 A	February 18, 1997		000	A61K031/00
DE 19680594 T	September 18, 1997		001	A61K031/19
EP 839031 A1	May 6, 1998	G	000	A61K031/00

DESIGNATED-STATES: AL AM AT AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG AT BE CH DE DK ES FR GB IT LI NL SE

CITED-DOCUMENTS: 7.Jnl.Ref

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9703659A1	July 18, 1996	1996WO-DE01304	
DE 29680627U1	July 18, 1996	1996DE-2080627	
DE 29680627U1	July 18, 1996	1996WO-DE01304	
DE 29680627U1		WO 9703659	Based on
AU 9665122A	July 18, 1996	1996AU-0065122	
AU 9665122A		WO 9703659	Based on
DE 19680594T	July 18, 1996	1996DE-1080594	
DE 19680594T	July 18, 1996	1996WO-DE01304	
DE 19680594T		WO 9703659	Based on
EP 839031A1	July 18, 1996	1996EP-0924744	
EP 839031A1	July 18, 1996	1996WO-DE01304	
EP 839031A1		WO 9703659	Based on

INT-CL (IPC): A61 K 31/00; A61 K 31/165; A61 K 31/19; A61 K 31/60

ABSTRACTED-PUB-NO: WO 9703659A
BASIC-ABSTRACT:

Symptomatic treatment of nasal polyps, chronic rhino-sinusitis or anosmia comprises admin. of a non-steroidal anti-inflammatory drug (NSAID).

Also claimed are the treatment of polyps, e.g. colon polyps and the prevention of malignant polyp dispersion by admin. of a NSAID.

USE - The NSAID inhibits the enzymatic activity of phospholipases, lipoxygenases and/or cyclo-oxygenases and thereby suppresses the prodn. of leukotriene (LT), predominantly chemotactically-active LTB₄, as well as prostaglandin and thromboxane. It is used esp. for the treatment of acute, allergic or inflammatory upper respiratory tract disorders, e.g. acute or allergic rhinitis, sinusitis or nasal polyps, which may be exacerbated by infection or which may occur as a result of long-term and regular intake of glucocorticoids. Typical dosage in the treatment of allergic or chronic rhinitis is 50-400 µg NSAID/nostiril 2 multiply daily. Effective therapy of anosmia comprises topical admin. of e.g. acetylsalicylic acid 2 multiply 1 mg/day for 2-8 weeks. Nasal polyps can be successfully treated topically with, e.g. acetylsalicylic acid applied initially at 2 multiply 1mg/day for 2 months and subsequent dosage redn. to 1 mg/day until the polyps have disappeared. Further, growth of nasal and intestinal polyps is prevented by the systemic admin. of NSAID, e.g. acetylsalicylic acid, in a daily dose of 300-900 mg, esp. 600 mg, e.g. over 3 months.

ADVANTAGE - The treatment is more effective and produces fewer side effects than conventional therapies.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: NON STEROIDAL ANTI INFLAMMATION DRUG PARACETAMOL DICLOFENAC IBUPROFEN
TREAT UPPER RESPIRATION TRACT DISORDER INTESTINAL COLON POLYP

DERWENT-CLASS: B05

CPI-CODES: B06-D01; B10-B02A; B10-C03; B10-C04C; B10-C04E; B10-D03; B14-C03;
B14-D05C; B14-D07A; B14-E10C; B14-H01; B14-K01; B14-L08; B14-N04;

CHEMICAL-CODES: Chemical Indexing M2 *01* Fragmentation Code G013 G100 H4 H401 H441
H8 J0 J011 J3 J341 M210 M211 M262 M281 M320 M414 M431 M510 M520 M531 M540 M782 M903
M904 M910 P616 P924 V811 Specific Compounds 00758M Registry Numbers 0758U Chemical
Indexing M2 *02* Fragmentation Code G011 G100 J0 J012 J1 J131 J2 J241 M210 M211 M262
M281 M320 M414 M431 M510 M520 M531 M540 M782 M903 M904 M910 P616 P924 V811 Specific
Compounds 00034M Registry Numbers 0034U Chemical Indexing M2 *03* Fragmentation Code
G011 G014 G100 H1 H102 H141 H6 H602 H608 H642 J0 J011 J1 M121 M143 M280 M311 M321
M342 M372 M391 M414 M431 M510 M520 M532 M540 M782 M903 M904 P616 P924 V811 Specific
Compounds 03008M Chemical Indexing M2 *04* Fragmentation Code G013 G100 J0 J011 J1
J171 M210 M214 M232 M240 M281 M312 M321 M331 M340 M342 M372 M391 M414 M431 M510 M520
M531 M540 M782 M903 M904 M910 P616 P924 V811 Specific Compounds 01987M Registry
Numbers 1987U Chemical Indexing M2 *05* Fragmentation Code D014 D022 D601 G013 G100
H2 H211 H5 H541 H6 H602 H641 H8 J0 J012 J1 J171 J3 J331 M210 M211 M240 M272 M281
M311 M321 M342 M372 M391 M412 M431 M511 M520 M531 M540 M782 M903 M904 M910 P616 P924
V811 Specific Compounds 00076M Registry Numbers 0076U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0034U; 0076U; 0758U; 1987U

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1997-046260

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
rhino adj sinusitis	14

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L3

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** **Thursday, August 07, 2003** [Printable Copy](#) [Create Case](#)**Set Name**
side by side**Query****Hit Count** **Set Name**
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR*

<u>L1</u>	nasalsinusitis	0	<u>L1</u>
<u>L2</u>	nasal adj sinusitis	10	<u>L2</u>
<u>L3</u>	rhino adj sinusitis	14	<u>L3</u>

END OF SEARCH HISTORY